Literature DB >> 12241661

Plasma urotensin II in heart failure.

A Mark Richards1, M Gary Nicholls, John G Lainchbury, Stephen Fisher, Timothy G Yandle.   

Abstract

Urotensin II has vasoconstrictive and negative inotropic effects, suggesting a possible role in circulatory regulation and pathophysiology of heart failure. We developed a sensitive specific RIA and measured plasma urotensin II in patients with heart failure and in controls. Plasma urotensin II was higher in heart failure patients (mean 3.9 pmol/L [SD 1.4]; than in controls (1.9 pmol/L [0.9]; p<0.0001). The role of urotensin II in heart failure, however, has yet to be defined.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12241661     DOI： 10.1016/s0140-6736(02)09709-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  27 in total

1.  Urotensin-II in systemic sclerosis: a new peptide in pathogenesis.

Authors:  Yavuz Pehlivan; Ahmet Mesut Onat; Gazi Comez; Taner Babacan
Journal:  Clin Rheumatol       Date:  2011-01-28       Impact factor: 2.980

Review 2.  Cardiovascular actions of human urotensin II--considerations for hypertension.

Authors:  Fraser D Russell; Peter Molenaar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-02-19       Impact factor: 3.000

3.  Urotensin II alters vascular reactivity in animals subjected to volume overload.

Authors:  Gregory S Harris; Robert M Lust; Laxmansa C Katwa; Christopher J Wingard
Journal:  Peptides       Date:  2010-08-17       Impact factor: 3.750

4.  Increased plasma levels of endothelin-1 and urotensin-II in patients with coronary heart disease.

Authors:  San Bao Chai; Xue Min Li; Yong Zheng Pang; Yong Fen Qi; Chao Shu Tang
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

5.  Urotensin II is raised in children with congenital heart disease.

Authors:  C M Simpson; D J Penny; C F Stocker; L S Shekerdemian
Journal:  Heart       Date:  2005-11-24       Impact factor: 5.994

6.  Renal impairment, hypertension and plasma urotensin II.

Authors:  Ari Mosenkis; Radhakrishna R Kallem; Theodore M Danoff; Nambi Aiyar; Jonathan Bazeley; Raymond R Townsend
Journal:  Nephrol Dial Transplant       Date:  2010-07-09       Impact factor: 5.992

Review 7.  Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.

Authors:  Damien Gruson; Frédéric Thys; Franck Verschuren
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

Review 8.  Recent advances in the diagnosis of heart failure.

Authors:  James O O'Neill; David O Taylor
Journal:  Curr Cardiol Rep       Date:  2004-05       Impact factor: 2.931

9.  Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues.

Authors:  D J Behm; J J McAtee; J W Dodson; M J Neeb; H E Fries; C A Evans; R R Hernandez; K D Hoffman; S M Harrison; J M Lai; C Wu; N V Aiyar; E H Ohlstein; S A Douglas
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

10.  Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice.

Authors:  David J Behm; Stephen M Harrison; Zhaohui Ao; Kristeen Maniscalco; Susan J Pickering; Evelyn V Grau; Tina N Woods; Robert W Coatney; Christopher P A Doe; Robert N Willette; Douglas G Johns; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.